¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 18

G u id e c h o i c e o n a d ju v a n t c h em o t h e r a p y
IN D IC A T IO N E v i d e n ce Q u a l i ty R e com m e n d a t i o n S t re n g h t
K i 67 IH C
N O
IN TERM ED IA TE
M O D ERA TE
IH C 4
N O
IN TERM ED IA TE
M O D ERA TE
IHC for Ki-67 analysis lacks reproducibility across laboratories and,
therefore, cannot be consistently interpreted when performed in a
broad range of laboratories.
1...,8,9,10,11,12,13,14,15,16,17 19,20,21,22,23,24
Powered by FlippingBook